Skip to content

MiMedx Group MDXG Common Stock

Common Stock at other companies

IAR
Integra LifeSciencesIART
240M0.0%
Organogenesis Holdings Inc. logo
Organogenesis Holdings Inc.ORGO
$13K0.0%
Artivion logo
ArtivionAORT
75M0.0%
Solventum logo
SolventumSOLV
750M0.0%
Vericel logo
VericelVCEL
75M0.0%
Enovis logo
EnovisENOV
133.3M0.0%

Other financials

Income statement

See full
Revenue$59.0M-33.1%
Gross profit$41.6M-41.9%
Operating income-$16.0M-295%
Net income-$10.9M-255%
EPS (diluted)-$0.07-240%

Balance sheet

See full
Cash & equivalents$159.8M+50.1%
Total debt$17.6M-5.7%
Total equity$242.9M+19.8%
Total assets$308.7M+14.1%

Cash flow

See full
Operating cash flow$1.9M-64.5%
CapEx$570.0K+51.2%
Free cash flow$1.3M-73.4%

Valuation

See full
Market cap$567.48M-33.9%
Enterprise value$425.3M-44.8%
P/E18.5×-2.9×
P/S1.5×-1.0×

Profitability

See full
Gross margin81%-0.9pp
Operating margin10.2%-5.1pp
Net margin7.9%-3.5pp
FCF margin17.8%-0.5pp

Returns & leverage

See full
Return on equity13.8%-8.6pp
Debt / equity0.1×0.0×
Current ratio5.4×+0.7×

Where this comes from

Reported directly by MiMedx Group in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: MiMedx Group’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about MiMedx Group's common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MiMedx Group's common stock?
MiMedx Group (MDXG) reported common stock of 250M in Q1 2026.
How has MiMedx Group's common stock changed year-over-year?
MiMedx Group's common stock decreased by 0.0% year-over-year, from 250M to 250M.
What is the long-term trend for MiMedx Group's common stock?
Over 5 years (2020 to 2025), MiMedx Group's common stock has grown at a 366.6% compound annual growth rate (CAGR), from 113K to 250M.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).